trending Market Intelligence /marketintelligence/en/news-insights/trending/tdsl9z3edumt8jgeyo2v0w2 content esgSubNav
In This List

Stemline Therapeutics launches $50M common stock offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Stemline Therapeutics launches $50M common stock offering

Stemline Therapeutics, Inc. launched an at-the-market offering to sell up to $50 million of its common stock.

In connection with the offering, the New York-based cancer drugs developer has entered a distribution agreement with J.P. Morgan Securities LLC, Cantor Fitzgerald & Co. and Ladenburg Thalmann & Co. Inc.